drugset / Trial / NCT06757881
IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1 Study of IL1RAP-targeting Chimeric Antigen Receptor T cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma
Timeline
- Start
- 2025-01-01
- Primary completion
- 2025-08-27
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells | Cell therapy | 1e+08 cells | — |
| Subject | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells | Cell therapy | 2.5e+08 cells | — |
| Subject | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells | Cell therapy | 5e+08 cells | — |